Business Context and Reporting Period
Company: XTL Biopharmaceuticals Ltd. (XTLB)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Accounting Standards: International Financial Reporting Standards (IFRS)
XTL Biopharmaceuticals Ltd., an Israeli company, has pivoted from a biopharmaceutical developer to an intellectual property and data collection firm. In August 2024, the Company acquired 100% of The Social Proxy Ltd., an AI web data and proxy services company. In March 2025 (post-balance sheet), XTL entered an exclusive sublicense agreement for its drug candidate hCDR1 with Biossil Inc., effectively exiting active drug development. The Company is a non-accelerated filer and is not a shell company.
Key Financial Metrics
| Metric (USD in thousands) | 2024 | 2023 |
|---|---|---|
| Revenues | 451 | 0 |
| Cost of Service | (448) | 0 |
| Gross Profit | 3 | 0 |
| Operating Loss | (2,172) | (765) |
| Net Loss (Total Comprehensive Loss) | (1,027) | (1,782) |
| Cash and Cash Equivalents (Year End) | 371 | 1,401 |
| Net Cash Used in Operating Activities | (1,618) | (707) |
| Working Capital (Deficit) | (867) | 1,840 |
| Total Assets | 8,550 | 2,426 |
| Total Shareholders' Equity | 5,435 | 2,220 |
| Accumulated Deficit | (159,009) | (158,246) |
Debt and Liquidity: As of December 31, 2024, the Company held $371,000 in cash and cash equivalents. Current liabilities totaled $2,207,000, including $1,279,000 in warrants classified as liabilities and $138,000 in bank loans. The Company reported a working capital deficit of $867,000.
Material Changes vs. Prior Period
- Revenue Generation: The Company generated $451,000 in revenue in 2024, entirely from The Social Proxy subsidiary, compared to zero revenue in 2023.
- Acquisition Impact: The August 2024 acquisition of The Social Proxy resulted in the recognition of $3,601,000 in intangible assets (technology, customer relationships, brand) and $3,193,000 in goodwill. This significantly increased total assets from $2.4 million to $8.6 million.
- Expense Structure: Operating expenses increased significantly due to the integration of The Social Proxy. Sales and marketing expenses rose from $0 to $487,000, and General and Administrative (G&A) expenses increased from $734,000 to $1,590,000.
- Non-Operating Income: Net finance income of $1,015,000 in 2024 (vs. $1,017,000 expense in 2023) was driven primarily by a $926,000 gain from the revaluation of warrants issued during the acquisition and fundraising.
- Share Capital: Issued and outstanding ordinary shares increased from 544.9 million to 881.4 million due to the Social Proxy transaction and a concurrent private placement.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
Management and the independent auditors have expressed substantial doubt about the Company's ability to continue as a going concern. The Company has an accumulated deficit of $159 million and incurred negative cash flows from operations of $1.6 million in 2024. Management plans to secure additional financing through equity or debt offerings, but there is no assurance such funds will be available on acceptable terms.
Strategic Shift and Outlook
Following the March 2025 sublicense of hCDR1 to Biossil Inc., XTL is no longer actively developing drug candidates. The Company's future focus is on the data collection and proxy services business via The Social Proxy. The Company expects to incur additional losses through 2025 and beyond.
Key Risks
- Regulatory and Legal: The data collection industry faces increasing scrutiny regarding web scraping, data privacy (GDPR, CCPA), and anti-scraping mechanisms. Litigation risks regarding intellectual property and data usage are significant.
- Geopolitical: Operations are based in Israel. Ongoing military conflicts and regional instability pose risks to personnel, operations, and the broader economy.
- Market Competition: The proxy and data collection market is highly competitive with established players (e.g., Bright Data, Oxylabs). The Social Proxy has a limited operating history.
- Liquidity: The Company requires additional capital to fund operations for the next 12 months. Failure to raise capital could force a cessation of operations.
Unusual Items
The 2024 financial results include a significant non-cash gain of $926,000 from the revaluation of warrants, which partially offset the operating loss. Additionally, the Company recorded $165,000 in amortization of intangible assets acquired in the Social Proxy transaction.
Investor Verification Checklist
- Capital Adequacy: Verify the Company's ability to raise the necessary capital to sustain operations beyond the current cash runway of approximately $371,000.
- Going Concern Status: Review the auditor's report and management's discussion on the "substantial doubt" regarding the Company's ability to continue as a going concern.
- Revenue Sustainability: Assess the growth trajectory and customer retention of The Social Proxy, which generated 100% of 2024 revenue but only $3,000 in gross profit.
- Warrant Liability: Monitor the fair value of the $1.97 million warrant liability, as fluctuations in stock price and volatility will directly impact reported net income/loss.
- Geopolitical Exposure: Evaluate the potential impact of the ongoing conflict in Israel on the Company's operations, personnel, and ability to execute its business plan.
- Post-Balance Sheet Events: Confirm the terms and potential milestone payments from the Biossil sublicense agreement for hCDR1, which represents a potential future revenue stream but ends active R&D.